nucleic acid extraction

The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million. 

The collaboration will leverage DiaSorin's Liaion MDX PCR system, and Tecan's Fluent Laboratory Automation Solution to provide users a complete sample-to-result system.

The firm received the CE IVD mark for Amplidiag Easy, an automated system that enables nucleic acid extraction and PCR setup directly from stool samples.

LGC will distribute Holliston, Mass.-based AutoGen's FlexStar, Arrow, and QuickGene platforms in Europe, the Middle East, and Africa. 

NEW YORK (GenomeWeb News) – LGC Genomics and Covaris announced late on Wednesday a partnership to develop solutions for the high-throughput extraction of nucleic acids from formalin-fixed, paraffin-embedded tissue samples.

A former scientist from Texas-based R&D firm Lynntech who was developing a nucleic acid sample prep module intended for use with molecular diagnostic assays for resource-poor areas of the world has left the company and founded his own startup to commercialize an improved vers

LGC Genomics said last week that it has expanded its nucleic acid extraction services to North America through the group's genomics laboratory in Beverly, Mass.
The new extraction service will complement existing capacity in Berlin and London, LGC said.

NEW YORK (GenomeWeb News) – Roche and Precision System Science today said that they will partner on the development of a PCR-based instrument from sample preparation in next-generation sequencing workflows.

NEW YORK (GenomeWeb News) – Pressure BioSciences said in a filing with the US Securities and Exchange Commission today that Cole-Parmer has signed an agreement to distribute the firm's PBI Shredder SG3 System on a non-exclusive basis.

NEW YORK (GenomeWeb News) – Phthisis Diagnostics recently announced a distribution agreement with the EliTech Group covering the Benelux countries of Belgium, the Netherlands, and Luxembourg.
Financial and other terms of the deal were not disclosed.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.